Open-Label Expanded Access Treatment With Pegunigalsidase Alfa for Fabry Disease Patients
Public ClinicalTrials.gov record NCT04552691. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Expanded Access Treatment With Open-Label Pegunigalsidase Alfa for Fabry Patients
Study identification
- NCT ID
- NCT04552691
- Recruitment status
- Approved For Marketing
- Study type
- Expanded access
- Phase
- Not listed
- Lead sponsor
- Chiesi Farmaceutici S.p.A.
- Industry
- Enrollment
- Not listed
Conditions and interventions
Conditions
Interventions
- Pegunigalsidase Alfa Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Not listed
- Primary completion
- Not listed
- Completion
- Not listed
- Last update posted
- Jul 30, 2024
United States locations
- U.S. sites
- 11
- U.S. states
- 10
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama-Birmingham | Birmingham | Alabama | 35294 | — |
| Phoenix Children's Hospital, Inc. | Phoenix | Arizona | 85006 | — |
| University of California Irvine | Orange | California | 92868 | — |
| Central Coas Nephrology | Salinas | California | 93901 | — |
| University of Florida, Division of Pediatric Genetics | Jacksonville | Florida | 32207 | — |
| Emory University School of Medicine | Atlanta | Georgia | 30322 | — |
| University of Iowa | Iowa City | Iowa | 52242 | — |
| Infusion Associates | Grand Rapids | Michigan | 49525 | — |
| Dallas Nephrology Associates | Dallas | Texas | 75235-2208 | — |
| University of Utah | Salt Lake City | Utah | 84108 | — |
| Lysosomal & Rare Disorder Research & Treatment Center (LRDRTC) | Fairfax | Virginia | 22030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04552691, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 30, 2024 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04552691 live on ClinicalTrials.gov.